Hugo Villanueva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hugo Villanueva has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Andrew G. Sikora
Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, 77030, USA
2 shared publications- Lacey Elizabeth Dobrolecki
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas
2 shared publications - Seth P. Lerner
Baylor College of Medicine
2 shared publications - Abhinav K. Jain
Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Abu Hena Mostafa Kamal
Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, 77030, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA; Advanced Technology Core, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA
1 shared publication - Allison Greer
Baylor College of Medicine 1 Lester and Sue Smith Breast Center Houston, Texas
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF18
LIG1 Loss in TP53 -mutant Triple-Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP–ATR Inhibitor Combinations
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.
- 3 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF18
Open AccessLIG1 Loss in TP53 -mutant Triple-Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP–ATR Inhibitor Combinations
Proteogenomic analyses have identified an association between LIG1 (DNA ligase I) loss and chemotherapy resistance in a subset of triple-negative breast cancer (TNBC) enriched for TP53 mutations. In this study, we demonstrate that co-occurrence of TP53 mutations and LIG1 loss is associated with upregulated DNA damage repair (DDR) activity, including homologous recombination (HR), likely contributing to reduced platinum sensitivity. Unbiased genetic and monotherapy drug screens identified poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) as a potential treatment for LIG1-depleted tumors; however, the increase in sensitivity was modest and lower than that observed in TNBC models with HR deficiency. Subsequently, a screen of PARP inhibition in combination with each of 120 clinically relevant DDR inhibitors revealed that PARPi sensitivity in LIG1-loss cells was significantly enhanced by the addition of an ATR inhibitor. Olaparib and ceralasertib demonstrated synergistic cytotoxicity in LIG1-loss cell line models; the combination significantly reduced tumor volume in a LIG1-low patient-derived xenograft (PDX )model compared with either monotherapy and showed greater ex vivo cytotoxicity in a LIG1-low PDX organoid model versus a LIG1-high control. Hence, this study highlights LIG1 status as a stratification factor for ongoing and future clinical trials of DDR-targeted combinations in TNBCs.
- 5 May 2026
- Published by Elsevier in Cancer Letters
- Vol. 653, 218562
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression
- 5 May 2026
- Published by Elsevier in Cancer Letters
- Vol. 653, 218562
Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression
- Open Access
- 14 March 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (12)
Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
Significance: Cisplatin is the first line therapy for patients with head and neck cancer. However, resistance to cisplatin remains a major concern. High expression of the calcium-activated chloride channel TMEM16A in tumors portends poor survival in these patients, possibly because of drug resistance. Here, we show that TMEM16A drives the sequestration of cisplatin into lysosomes. Subsequently, cisplatin is expelled via the delivery of lysosomes to the cell surface. We show that TMEM16A enhances this process, thereby promoting cisplatin resistance. We also show that lysosomal inhibition synergizes with cisplatin to induce tumor cell death. Our data uncovers a new fundamental feature of both lysosomal physiology and cancer cell biology that can potentially impact the treatment of patients with head and neck cancer.
- 14 March 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (12)
Open AccessLysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy
Significance: Cisplatin is the first line therapy for patients with head and neck cancer. However, resistance to cisplatin remains a major concern. High expression of the calcium-activated chloride channel TMEM16A in tumors portends poor survival in these patients, possibly because of drug resistance. Here, we show that TMEM16A drives the sequestration of cisplatin into lysosomes. Subsequently, cisplatin is expelled via the delivery of lysosomes to the cell surface. We show that TMEM16A enhances this process, thereby promoting cisplatin resistance. We also show that lysosomal inhibition synergizes with cisplatin to induce tumor cell death. Our data uncovers a new fundamental feature of both lysosomal physiology and cancer cell biology that can potentially impact the treatment of patients with head and neck cancer.